Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
AVENUE THERAPEUTICS, INC. (ATXI)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 0.0 | -4.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | -4.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | 100.0% | | | | | | |
| Selling, general and administrative [+] | 0.9 | 1.0 | 3.4 | 0.5 | 0.5 | 1.1 | 0.5 | 0.6 |
| General and administrative | 0.9 | 1.0 | 3.4 | 0.5 | 0.5 | 1.1 | 0.5 | 0.6 |
| Research and development | 3.0 | 1.2 | 0.5 | 0.2 | 0.2 | 1.8 | 0.4 | 0.3 |
| EBIT [+] | -3.9 | -6.4 | -3.9 | -0.7 | -0.6 | -2.9 | -0.9 | -0.9 |
| EBIT growth | 548.4% | 124.6% | 328.0% | -24.0% | -36.4% | 186.0% | -8.5% | -15.9% |
| EBIT margin | | 152.0% | | | | | | |
| Interest income | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Interest income | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other income (expense), net [+] | -0.2 | -1.2 | 4.4 | | | | | |
| Change in fair value of warrants | -0.2 | -0.9 | -5.6 | | | | | |
| Pre-tax income | -4.0 | -7.6 | 0.5 | -0.7 | -0.6 | -2.9 | -0.9 | -0.9 |
| Income taxes | 0.0 | 0.0 | -0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Minority interest | 0.0 | 0.1 | -0.1 | | | | | |
| Net income | -4.0 | -7.5 | 0.6 | -0.7 | -0.6 | -2.9 | -0.9 | -0.9 |
| Net margin | | 178.2% | | | | | | |
| |
| Basic EPS [+] | ($0.52) | ($1.35) | $0.26 | ($0.45) | ($0.41) | ($2.05) | ($0.81) | ($0.79) |
| Growth | 26.8% | -33.9% | -132.7% | -42.5% | 615.3% | 3297.1% | 1239.3% | 1162.7% |
| Diluted EPS [+] | ($0.52) | ($1.35) | $0.26 | ($0.45) | ($0.41) | ($2.05) | ($0.81) | ($0.79) |
| Growth | 26.8% | -33.9% | -132.7% | -42.5% | 615.3% | 3297.1% | 1239.3% | 1162.7% |
| |
| Shares outstanding (basic) [+] | 7.7 | 5.6 | 2.2 | 1.5 | 1.5 | 1.4 | 1.1 | 1.1 |
| Growth | 423.1% | 298.3% | 92.8% | 32.2% | -91.1% | -91.6% | -93.1% | -93.3% |
| Shares outstanding (diluted) [+] | 7.7 | 5.6 | 2.2 | 1.5 | 1.5 | 1.4 | 1.1 | 1.1 |
| Growth | 423.1% | 298.3% | 92.8% | 32.2% | -91.1% | -91.6% | -93.1% | -93.3% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|